JP2012228272A5 - - Google Patents

Download PDF

Info

Publication number
JP2012228272A5
JP2012228272A5 JP2012187518A JP2012187518A JP2012228272A5 JP 2012228272 A5 JP2012228272 A5 JP 2012228272A5 JP 2012187518 A JP2012187518 A JP 2012187518A JP 2012187518 A JP2012187518 A JP 2012187518A JP 2012228272 A5 JP2012228272 A5 JP 2012228272A5
Authority
JP
Japan
Prior art keywords
framework
single chain
chain framework
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012187518A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012228272A (ja
JP6075836B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012228272A publication Critical patent/JP2012228272A/ja
Publication of JP2012228272A5 publication Critical patent/JP2012228272A5/ja
Application granted granted Critical
Publication of JP6075836B2 publication Critical patent/JP6075836B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2012187518A 2002-05-22 2012-08-28 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法 Expired - Lifetime JP6075836B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US38264902P 2002-05-22 2002-05-22
US60/382,649 2002-05-22
US43825603P 2003-01-03 2003-01-03
US60/438,256 2003-01-03

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2010060713A Division JP2010187678A (ja) 2002-05-22 2010-03-17 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013019425A Division JP6100544B2 (ja) 2002-05-22 2013-02-04 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法

Publications (3)

Publication Number Publication Date
JP2012228272A JP2012228272A (ja) 2012-11-22
JP2012228272A5 true JP2012228272A5 (https=) 2013-03-21
JP6075836B2 JP6075836B2 (ja) 2017-02-08

Family

ID=29553590

Family Applications (10)

Application Number Title Priority Date Filing Date
JP2004506369A Withdrawn JP2006508638A (ja) 2002-05-22 2003-05-21 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
JP2010060713A Withdrawn JP2010187678A (ja) 2002-05-22 2010-03-17 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
JP2012187518A Expired - Lifetime JP6075836B2 (ja) 2002-05-22 2012-08-28 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
JP2013019425A Expired - Lifetime JP6100544B2 (ja) 2002-05-22 2013-02-04 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
JP2013193935A Pending JP2013256533A (ja) 2002-05-22 2013-09-19 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
JP2015161601A Pending JP2015214583A (ja) 2002-05-22 2015-08-19 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
JP2015161600A Expired - Lifetime JP6261136B2 (ja) 2002-05-22 2015-08-19 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
JP2017161036A Pending JP2017201990A (ja) 2002-05-22 2017-08-24 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
JP2019009288A Expired - Lifetime JP6918033B2 (ja) 2002-05-22 2019-01-23 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
JP2020085288A Pending JP2020171286A (ja) 2002-05-22 2020-05-14 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2004506369A Withdrawn JP2006508638A (ja) 2002-05-22 2003-05-21 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
JP2010060713A Withdrawn JP2010187678A (ja) 2002-05-22 2010-03-17 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法

Family Applications After (7)

Application Number Title Priority Date Filing Date
JP2013019425A Expired - Lifetime JP6100544B2 (ja) 2002-05-22 2013-02-04 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
JP2013193935A Pending JP2013256533A (ja) 2002-05-22 2013-09-19 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
JP2015161601A Pending JP2015214583A (ja) 2002-05-22 2015-08-19 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
JP2015161600A Expired - Lifetime JP6261136B2 (ja) 2002-05-22 2015-08-19 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
JP2017161036A Pending JP2017201990A (ja) 2002-05-22 2017-08-24 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
JP2019009288A Expired - Lifetime JP6918033B2 (ja) 2002-05-22 2019-01-23 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
JP2020085288A Pending JP2020171286A (ja) 2002-05-22 2020-05-14 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法

Country Status (14)

Country Link
US (5) US8853362B2 (https=)
EP (5) EP3656787A1 (https=)
JP (10) JP2006508638A (https=)
CN (4) CN103739706B (https=)
AU (2) AU2003238370B2 (https=)
CA (2) CA2483285C (https=)
CY (1) CY1114225T1 (https=)
DK (2) DK1506236T3 (https=)
ES (3) ES2656427T3 (https=)
HU (1) HUE048922T2 (https=)
NZ (1) NZ536412A (https=)
PT (2) PT2332989E (https=)
SI (2) SI2332989T1 (https=)
WO (1) WO2003097697A2 (https=)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0226727D0 (en) * 2002-11-15 2002-12-24 Medical Res Council Intrabodies
EP2336323A3 (en) * 2005-03-25 2012-05-23 National Research Council Of Canada Method for isolation of soluble polypeptides
AU2016204739C1 (en) * 2005-06-07 2017-10-19 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting TNFalpha
NZ563580A (en) 2005-06-07 2010-09-30 Esbatech An Alcon Biomedical R Stable and soluble antibodies inhibiting TNFaplha
AU2013207650B2 (en) * 2005-06-07 2016-04-21 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting TNFalpha
AU2011265593B2 (en) * 2005-06-07 2013-08-15 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting TNFalpha
ES2547248T3 (es) 2006-04-28 2015-10-02 Delenex Therapeutics Ag Anticuerpos que se unen al dominio extracelular del receptor Tirosina cinasa ALK
JP2009542232A (ja) 2006-07-10 2009-12-03 エスバテック・アーゲー 上皮および／または内皮層を通過するｓｃＦｖ抗体
IN2009DN05758A (https=) * 2007-03-12 2015-07-24 Esbatech Ag
WO2008131575A2 (en) * 2007-04-27 2008-11-06 Esbatech Ag Anti-alk antibodies suitable for treating metastatic cancers or tumors
KR101530723B1 (ko) 2007-06-25 2015-06-22 에스바테크 - 어 노바티스 컴파니 엘엘씨 단일 쇄 항체의 서열에 기초한 공학처리 및 최적화
US20090074780A1 (en) * 2007-06-25 2009-03-19 David Urech Methods of modifying antibodies, and modified antibodies with improved functional properties
EP2197914A1 (en) 2007-09-13 2010-06-23 Delenex Therapeutics AG HUMANIZED ANTIBODIES AGAINST THE ß-AMYLOYD PEPTIDE
AU2013202997B2 (en) * 2008-06-25 2015-01-22 Novartis Ag STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFalpha
AU2015201794B2 (en) * 2008-06-25 2017-01-19 Novartis Ag STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFa
LT3216803T (lt) * 2008-06-25 2020-06-10 Novartis Ag Stabilūs ir tirpūs antikūnai, slopinantys vegf
PL3628686T3 (pl) 2008-06-25 2022-02-28 Novartis Ag Humanizowanie przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała
MX345039B (es) * 2008-06-25 2017-01-16 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles que inhiben el tnfa.
AU2016273957C1 (en) * 2008-06-25 2019-04-18 Novartis Ag STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFa
PT2752428T (pt) * 2008-06-25 2020-02-14 Novartis Ag Humanização de anticorpos de coelho com utilização de um framework de anticorpos universal
PL3241843T3 (pl) 2008-06-25 2021-12-27 Novartis Ag Optymalizacja rozpuszczalności cząsteczek immunowiążących
CN104004094B (zh) * 2008-06-25 2017-09-22 艾斯巴技术-诺华有限责任公司 使用通用抗体构架进行的兔抗体的人源化
WO2010006454A2 (en) 2008-06-30 2010-01-21 Esbatech, An Alcon Biomedical Research Unit Llc Functionalized polypeptides
MX2011000009A (es) 2008-07-10 2011-08-15 Esbatech Alcon Biomed Res Unit Metodos y composiciones para la administracion mejorada de macromoleculas.
EP3181583A1 (en) 2009-02-24 2017-06-21 ESBATech, an Alcon Biomedical Research Unit LLC Methods for identifying immunobinders of antigens
SG2014014864A (en) * 2009-02-24 2014-09-26 Esbatech Alcon Biomed Res Unit Methods for identifying immunobinders of cell-surface antigens
US8399624B1 (en) 2009-06-25 2013-03-19 Esbatech, An Alcon Biomedical Research Unit Llc Acceptor framework for CDR grafting
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
EP2476754A1 (en) * 2011-01-14 2012-07-18 Bundesrepublik Deutschland, Letztvertreten Durch Den Präsidenten Des Paul-Ehrlich-Instituts Methods for the identification and repair of amino acid residues destabilizing single-chain variable fragments (scFv)
CN103890246A (zh) 2011-08-18 2014-06-25 亲和生物科学公司 可溶性多肽
MX2014004521A (es) 2011-10-20 2014-05-28 Esbatech A Novartis Co Llc Anticuerpo estable de union a antigenos multiples.
EP3165535B1 (en) * 2012-08-22 2019-05-15 Mogam Biotechnology Research Institute Screening and engineering method of super-stable immunoglobulin variable domains and their uses
CA2888583C (en) 2012-11-05 2022-03-29 Delenex Therapeutics Ag Binding members to il-1 beta
WO2014095808A1 (en) 2012-12-17 2014-06-26 Delenex Therapeutics Ag Antibodies against il-1 beta
HK1217960A1 (zh) * 2013-02-15 2017-01-27 Esbatech - A Novartis Company Llc 用於cdr移植的接受体框架
JP2016506752A (ja) * 2013-02-20 2016-03-07 エスバテック − ア ノバルティスカンパニー エルエルシー Ｃｄｒグラフトのためのアクセプターフレームワーク
HRP20251426T1 (hr) 2013-05-06 2026-01-02 Scholar Rock, Inc. Sastavi i postupci za modulaciju faktora rasta
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
IL313511A (en) 2014-11-12 2024-08-01 Seagen Inc Compounds acting on glycans and methods of using them
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
IL299203A (en) 2015-10-13 2023-02-01 Eureka Therapeutics Inc ׂ A Delaware Corp Antibody factors specific for human differentiation group 19 and their uses
EP3842450A1 (en) 2015-10-23 2021-06-30 Eureka Therapeutics, Inc. Antibody/t-cell receptor chimeric constructs and uses thereof
EP3373969A4 (en) 2015-11-12 2019-08-14 Siamab Therapeutics, Inc. GLYCANINTERAGING COMPOUNDS AND METHOD OF USE
KR20190003938A (ko) 2016-02-25 2019-01-10 셀 메디카 스위처란트 아게 면역치료를 위한 변형된 세포
IL265484B2 (en) * 2016-09-21 2026-01-01 Aptevo Res & Development Llc CD123 binding proteins, related methods and compositions
EP3541847A4 (en) 2016-11-17 2020-07-08 Seattle Genetics, Inc. COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
KR102653141B1 (ko) 2017-03-03 2024-04-01 씨젠 인크. 글리칸-상호작용 화합물 및 사용 방법
CN112218621A (zh) * 2018-04-10 2021-01-12 西北大学 包含基于靶向亲和域的膜蛋白的胞外囊泡
WO2020069349A1 (en) * 2018-09-27 2020-04-02 Colorado State University Research Foundation Scfv's for live cell imaging and other uses
US12285437B2 (en) 2019-10-30 2025-04-29 The Research Foundation For The State University Of New York Reversing the undesirable pH-profile of doxorubicin via activation of a disubstituted maleamic acid prodrug at tumor acidity
PH12023550015A1 (en) 2020-07-16 2024-03-11 Novartis Ag Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
CA3172265A1 (en) 2021-03-10 2022-09-15 Dimitri BIELI Antibodies against tdp-43 and methods of using the same
WO2023139292A1 (en) 2022-01-24 2023-07-27 Cambridge Enterprise Limited Tau therapy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5817311A (en) * 1993-03-05 1998-10-06 Universite Catholique De Louvain Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies
DE4425115A1 (de) 1994-07-15 1996-01-18 Boehringer Mannheim Gmbh Verfahren zur Modifizierung der Stabilität von Antikörpern
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
US6696248B1 (en) * 1995-08-18 2004-02-24 Morphosys Ag Protein/(poly)peptide libraries
US6262238B1 (en) 1997-01-14 2001-07-17 Roche Diagnostic, Gmbh Process for modifying the stability of antibodies
AU3587599A (en) 1997-11-28 1999-06-16 Invitrogen Corporation Single chain monoclonal antibody fusion reagents that regulate transcript ion in vivo
GB2344886B (en) 1999-03-10 2000-11-01 Medical Res Council Selection of intracellular immunoglobulins
EP2392596A3 (en) 1999-12-28 2013-11-27 ESBATech, an Alcon Biomedical Research Unit LLC Intrabodies with defined framework that is stable in a reducing environment and applications thereof
GB0008419D0 (en) 2000-04-05 2000-05-24 Bioinvent Int Ab A method for invitro molecular evolution of antibody function
EP1156062A1 (en) 2000-05-12 2001-11-21 GPC Biotech AG Immunomodulatory human MHC class II antigen-binding peptides/proteins
US6410271B1 (en) 2000-06-23 2002-06-25 Genetastix Corporation Generation of highly diverse library of expression vectors via homologous recombination in yeast
DE10039191C1 (de) 2000-08-10 2002-01-17 Infineon Technologies Ag Hochfrequenz-Eingangsstufe

Similar Documents

Publication Publication Date Title
JP2012228272A5 (https=)
JP2014515602A5 (https=)
López-Marqués et al. Structure and mechanism of ATP-dependent phospholipid transporters
JP2018531624A5 (https=)
BRPI0813898A2 (pt) métodos para selecionar um peptídeo ou polipeptídeo resistente à protease de um repertório de peptídeo ou polipeptídeos, para produzir um repertório de peptídeos ou polipeptídeos resistentes à protease, para fabricar um peptídeo ou polipeptídeo resistente à protease, e para tratar uma doença, peptídeo ou polipeptídeo resistente à protease, domínio variável simples de imunoglobulina resistente à protease isolada, antagonista, uso de um antagonista, ácido nucleico, vetor, e, célula hospedeira.
JP2010227108A5 (https=)
JP2016053091A5 (https=)
WO2013182910A3 (en) Transcription activator-like effector (tale) fusion protein
JP2016502843A5 (https=)
JP2018138049A5 (https=)
JP2017048194A5 (https=)
JP2020501532A5 (https=)
JP2013172734A5 (https=)
FI3683235T3 (fi) Anti-IL-33-vasta-aineita ja niiden käyttöjä
MX350962B (es) Metodo para fabricar moleculas heterodimericas de fragmentos cristalizables de anticuerpo, utilizando efectos electrostaticos de direccion.
WO2015089486A3 (en) Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
EA201590138A1 (ru) Оптимизация антител, которые связывают ген активации лимфоцитов 3 (lag-3), и их применение
WO2016168755A8 (en) Method for mass humanization of non-human antibodies
JP2016104790A5 (https=)
RU2016146198A (ru) Терапевтические dll4-связывающие белки
EA201400568A1 (ru) Альбуминсвязывающие антитела и их связывающие фрагменты
EP2756101A4 (en) SAMPLE: ANTIPROBE COMPOSITIONS FOR DETECTION OF HIGH-SPECIFIC DNA OR RNA
JP2013539454A5 (https=)
WO2012142434A3 (en) Aav mediated ctla-4 gene transfer to treat sjogren's syndrome
UA118286C2 (uk) Білок агоніст рецептора trail